Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer

Epithelial ovarian cancer (EOC) is one of the deadliest gynaecological malignancies. The late diagnosis is frequent due to the absence of specific symptomatology and the molecular complexity of the disease, which includes a high angiogenesis potential. The first-line treatment is based on optimal de...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicines 2021-12, Vol.10 (1), p.77
Main Authors: Garrido, Maritza P, Fredes, Allison N, Lobos-González, Lorena, Valenzuela-Valderrama, Manuel, Vera, Daniela B, Romero, Carmen
Format: Article
Language:English
Subjects:
Adenosine
Angiogenesis
anti-angiogenic therapy
Cancer therapies
Chemotherapy
Cysts
Drug delivery
drug repurposing
epithelial ovarian cancer
Gemcitabine
Gynecology
Kinases
Medical prognosis
Metastasis
Mutation
nanocarriers
Nanotechnology
non-coding RNAs
Ovarian cancer
Patients
Poly(ADP-ribose) polymerase
Proteins
Review
Ribose
Surgery
Survival
Tumors
Vascular endothelial growth factor
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Epithelial ovarian cancer (EOC) is one of the deadliest gynaecological malignancies. The late diagnosis is frequent due to the absence of specific symptomatology and the molecular complexity of the disease, which includes a high angiogenesis potential. The first-line treatment is based on optimal debulking surgery following chemotherapy with platinum/gemcitabine and taxane compounds. During the last years, anti-angiogenic therapy and poly adenosine diphosphate-ribose polymerases (PARP)-inhibitors were introduced in therapeutic schemes. Several studies have shown that these drugs increase the progression-free survival and overall survival of patients with ovarian cancer, but the identification of patients who have the greatest benefits is still under investigation. In the present review, we discuss about the molecular characteristics of the disease, the recent evidence of approved treatments and the new possible complementary approaches, focusing on drug repurposing, non-coding RNAs, and nanomedicine as a new method for drug delivery.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines10010077